Literature DB >> 1709692

Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

K E Wright1, M J Buchmeier.   

Abstract

The role of antiviral antibody in resistance to acute lymphocytic choriomeningitis virus infection has been examined by passive transfer of monoclonal antibodies and intracerebral challenge infection. Protection of mice from lethal T-cell-mediated acute disease was observed following passive administration of antibodies either 1 day before or up to 2 days after infection. Viral replication was suppressed in protected mice, and the cytotoxic T-cell response to virus was also diminished. Virus was cleared from the brain and other tissues of protected mice without development of lethal immunopathology, suggesting that preexisting antibody may play a significant role in modulating potentially destructive effects of T-cell-mediated immune responses to pathogens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709692      PMCID: PMC240949     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  The virology and immunobiology of lymphocytic choriomeningitis virus infection.

Authors:  M J Buchmeier; R M Welsh; F J Dutko; M B Oldstone
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

2.  Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization.

Authors:  M Bruns; J Cihak; G Müller; F Lehmann-Grube
Journal:  Virology       Date:  1983-10-15       Impact factor: 3.616

3.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

4.  Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.

Authors:  A L Schmaljohn; E D Johnson; J M Dalrymple; G A Cole
Journal:  Nature       Date:  1982-05-06       Impact factor: 49.962

Review 5.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

6.  Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis.

Authors:  W A Boere; B J Benaissa-Trouw; M Harmsen; C A Kraaijeveld; H Snippe
Journal:  J Gen Virol       Date:  1983-06       Impact factor: 3.891

7.  Immune T cells can protect or induce fatal neurological disease in murine lymphocytic choriomeningitis.

Authors:  J E Allan; P C Doherty
Journal:  Cell Immunol       Date:  1985-02       Impact factor: 4.868

8.  Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice.

Authors:  F Lehmann-Grube; U Assmann; C Löliger; D Moskophidis; J Löhler
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo.

Authors:  J A Byrne; M B Oldstone
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

Review 10.  Antibody-mediated destruction of virus-infected cells.

Authors:  J G Sissons; M B Oldstone
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

View more
  23 in total

1.  Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

Authors:  P Seiler; B M Senn; P Klenerman; U Kalinke; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 2.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.

Authors:  D Huw Davies; Megan M McCausland; Conrad Valdez; Devan Huynh; Jenny E Hernandez; Yunxiang Mu; Siddiqua Hirst; Luis Villarreal; Philip L Felgner; Shane Crotty
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge.

Authors:  M G von Herrath; M Yokoyama; J Dockter; M B Oldstone; J L Whitton
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

Review 5.  Antibody-mediated clearance of viruses from the mammalian central nervous system.

Authors:  B Dietzschold
Journal:  Trends Microbiol       Date:  1993-05       Impact factor: 17.079

6.  Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice.

Authors:  P Seiler; U Kalinke; T Rülicke; E M Bucher; C Böse; R M Zinkernagel; H Hengartner
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus.

Authors:  P Borrow; M B Oldstone
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection.

Authors:  J R Baldridge; M J Buchmeier
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Authors:  Joseph W Golden; Piet Maes; Steven A Kwilas; John Ballantyne; Jay W Hooper
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

10.  Respiratory syncytial virus infection in anti-mu-treated mice.

Authors:  B S Graham; L A Bunton; J Rowland; P F Wright; D T Karzon
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.